Showing results (541-550 of 566) with videos related to

Sort By:
Pageof 57
Clinical Lung Cancer|January 9, 2019
Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME TrialClaudio Vernieri, Diego Signorelli, Giulia Galli, et al.
Clinical Lung Cancer|April 16, 2020
DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External ValidationArsela Prelaj, Giuseppe Lo Russo, Claudia Proto, et al.
Cancers|December 11, 2019
EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation CohortArsela Prelaj, Roberto Ferrara, Sara Elena Rebuzzi, et al.
Frontiers in Medicine|August 19, 2021
Patient Preferences for Lung Cancer Treatments: A Study Protocol for a Preference Survey Using Discrete Choice Experiment and Swing WeightingDario Monzani, Serena Petrocchi, Serena Oliveri, et al.
Clinical Lung Cancer|August 10, 2022
Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung CancerGiulia Galli, Paola Antonia Corsetto, Claudia Proto, et al.
The Oncologist|October 5, 2023
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort StudyFederica Pecci, Luca Cantini, Valeria Cognigni, et al.
Clinical Lung Cancer|August 2, 2021
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon HistologySara Manglaviti, Marta Brambilla, Diego Signorelli, et al.
Cancers|January 21, 2022
Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with ImmunotherapyArsela Prelaj, Mattia Boeri, Alessandro Robuschi, et al.
Physical Biology|December 6, 2017
Roadmap on semiconductor-cell biointerfacesBozhi Tian, Shuai Xu, John A Rogers, et al.
Lung Cancer (Amsterdam, Netherlands)|November 2, 2023
High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitorsSara Manglaviti, Marta Bini, Giulia Apollonio, et al.
Pageof 57